Breast Cancer Tissues and Organoids BioBank: Constitution, Research Activities and Samples Access

In 2023, at the Center for Biological Resources (CRB) at the Institute of Genetics and Biophysics (IGB, Naples, Italy) of the National Research Council (CNR), the Breast Cancer Tissues and Organoids Biobank (BCTO BioBank) was founded. This is a new generation Biobank, dedicated to the collection, ch...

Full description

Saved in:
Bibliographic Details
Published inOrganoids Vol. 4; no. 1; p. 5
Main Authors Miranda, Lucia, Mandrich, Luigi, Massa, Simona, Nutile, Teresa, Crovella, Clotilde, De Rosa, Ilaria, Lucci, Raffaella, De Rosa, Filippo, Somma, Pasquale, Mercadante, Vincenzo, Abate, Ciro, Arbucci, Salvatore, Panico, Luigi, Caputo, Emilia
Format Journal Article
LanguageEnglish
Published MDPI AG 01.03.2025
Subjects
Online AccessGet full text
ISSN2674-1172
2674-1172
DOI10.3390/organoids4010005

Cover

More Information
Summary:In 2023, at the Center for Biological Resources (CRB) at the Institute of Genetics and Biophysics (IGB, Naples, Italy) of the National Research Council (CNR), the Breast Cancer Tissues and Organoids Biobank (BCTO BioBank) was founded. This is a new generation Biobank, dedicated to the collection, characterization, storage, and distribution of tissues and their 3D ‘organoid’ patients-derived. Tumor and healthy tissues from breast cancer patients have been collected from surgeons at Monaldi Hospital (Naples, Italy) and used to generate the corresponding tumor and healthy organoids from the same patient. After their establishment in culture, both organoids were characterized for their receptor status on a microfluidic 2-lane OrganoPlate, by immunofluorescence. The resulting data were compared with the expression profile obtained by immunohistochemistry on respective parental tissues. These data allowed us to phenotypically validate the generated organoids and classify them in a dedicated database, where also the clinical data of the corresponding patients were collected. During the six months of activities, we collected and characterized 27 samples. The continuous BCTO BioBank activity is fundamental to generating a high number of samples, for a broader and efficiently elaborated patient stratification at molecular level, biomarker discovery investigations, and for tailored treatment protocols design.
ISSN:2674-1172
2674-1172
DOI:10.3390/organoids4010005